文献速递肝肾功能剂量调整特殊人群用药

T-DM1在HER2阳性转移性乳腺癌伴肝功能不全患者中的I期药代动力学研究

A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

这项I期平行队列研究按Child-Pugh标准纳入肝功能正常、轻度不全和中度不全的HER2阳性转移性乳腺癌患者,每3周静脉给予T-DM1 3.6 mg/kg。结果显示,轻度和中度肝功能不全患者第1周期T-DM1清除率分别比肝功能正常者快1.8倍和4.0倍,但第3周期各组清除率相似。各队列血浆DM1及含DM1分解产物浓度均较低且相当,提示轻中度肝功能不全患者未出现系统性DM1浓度升高。

要点

  • 轻中度肝功能不全患者第1周期T-DM1清除率分别快1.8倍和4.0倍,但该差异在第3周期不明显。
  • 各肝功能队列血浆DM1及含DM1分解产物浓度均较低且相当,未见系统性DM1暴露升高。
  • 重复给药三周期后,轻中度肝功能不全患者T-DM1暴露在肝功能正常者范围内。

核心结论

  • 轻中度肝功能不全患者未见系统性DM1浓度较肝功能正常者升高。
  • 肝功能不全患者第1周期观察到的T-DM1清除加快似乎是短暂的。
  • 重复给药三周期后,轻中度肝功能不全患者T-DM1暴露处于肝功能正常者所见范围内。

研究设计与样本

  • I期平行队列药代动力学研究,按Child-Pugh标准分为肝功能正常、轻度不全和中度不全三个独立队列。
  • 患者每3周静脉接受T-DM1 3.6 mg/kg,在第1和第3周期采集药代动力学样本。
  • 肝功能正常队列n=10,轻度不全队列n=10,中度不全队列n=8。

主要发现

  • 与肝功能正常者相比,第1周期T-DM1清除率在轻度队列快1.8倍、中度队列快4.0倍。
  • 第3周期T-DM1清除率各组相似,正常、轻度、中度队列均值±标准差分别为8.16±3.27(n=9)、9.74±3.62(n=7)及8.99和10.2(个别值,n=2)mL/day/kg。
  • 第1周期T-DM1清除率与基线白蛋白、天冬氨酸氨基转移酶和HER2胞外域浓度显著相关(p<0.05)。
  • 各队列血浆DM1及含DM1分解产物浓度均较低且相当。

临床怎么用

  • 轻中度肝功能不全患者使用T-DM1时,重复给药后暴露与肝功能正常者范围重叠,未见系统性DM1浓度升高。
  • 第1周期清除加快呈一过性,临床解读早期药代动力学差异时应考虑采血周期。

局限性

  • 中度肝功能不全队列仅8例,第3周期仅2例有个别值,样本量小。
  • 研究为I期药代动力学研究,未报告疗效或安全性终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and relevant analytes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and hepatic impairment. METHODS: Patients were enrolled in three independent parallel cohorts based on hepatic function per Child-Pugh criteria: normal hepatic function, mild hepatic impairment, and moderate hepatic impairment. Patients received T-DM1 3.6 mg/kg intravenously every 3 weeks. PK samples were collected during cycles 1 and 3, and the PK of T-DM1 and relevant analytes were characterized and compared across cohorts. RESULTS: Compared with patients with normal hepatic function (n = 10), T-DM1 clearance at cycle 1 was 1.8- and 4.0-fold faster in the mild (n = 10) and moderate (n = 8) cohorts, respectively. The trend of faster clearance was less apparent in cycle 3, with similar T-DM1 clearance across cohorts (mean ± standard deviation 8.16 ± 3.27 [n = 9], 9.74 ± 3.62 [n = 7], and 8.99 and 10.2 [individual values, n = 2] mL/day/kg for the normal, mild, and moderate cohorts, respectively). T-DM1 clearance at cycle 1 correlated significantly with baseline albumin, aspartate aminotransferase, and HER2 extracellular domain concentrations (p < 0.05). Plasma concentrations of DM1 and DM1-containing catabolites were low and were comparable across cohorts. CONCLUSIONS: No increase in systemic DM1 concentration was observed in patients with mild or moderate hepatic impairment versus those with normal hepatic function. The faster T-DM1 clearance observed at cycle 1 in patients with hepatic impairment appeared to be transient. After repeated dosing (three cycles), T-DM1 exposure in patients with mild and moderate hepatic impairment was within the range seen in those with normal hepatic function.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Li C, Agarwal P, Gibiansky E, et al. A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. Clin Pharmacokinet. 2017. PMID: 27995530. doi:10.1007/s40262-016-0496-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。